LON:AZN - AstraZeneca Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
GBX 5,591 +45.00 (+0.81 %)
(As of 10/15/2018 11:03 AM ET)
Previous CloseGBX 5,546
Today's RangeGBX 5,518 - GBX 5,635
52-Week RangeGBX 4,260 - GBX 5,520
Volume786,390 shs
Average Volume2.31 million shs
Market Capitalization£61.66 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.

Receive AZN News and Ratings via Email

Sign-up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange LON
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
SymbolLON:AZN
CUSIPN/A
Phone+44-20-73045000

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins21.83%
Return on Equity36.38%
Return on Assets7.91%

Miscellaneous

EmployeesN/A
Outstanding Shares1,270,000,000
Market Cap£61.66 billion

AstraZeneca (LON:AZN) Frequently Asked Questions

What is AstraZeneca's stock symbol?

AstraZeneca trades on the London Stock Exchange (LON) under the ticker symbol "AZN."

How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?

AstraZeneca declared a dividend on Thursday, July 26th. Investors of record on Thursday, August 9th will be paid a dividend of GBX 68.40 per share on Monday, September 10th. This represents a yield of 1.19%. The ex-dividend date of this dividend is Thursday, August 9th. The official announcement can be viewed at this link. View AstraZeneca's Dividend History.

What price target have analysts set for AZN?

22 brokers have issued 1 year price objectives for AstraZeneca's stock. Their forecasts range from GBX 4,080 to GBX 6,600. On average, they anticipate AstraZeneca's share price to reach GBX 5,772.32 in the next year. This suggests a possible upside of 3.2% from the stock's current price. View Analyst Price Targets for AstraZeneca.

What is the consensus analysts' recommendation for AstraZeneca?

22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 2 sell ratings, 7 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AstraZeneca.

Who are some of AstraZeneca's key competitors?

Who are AstraZeneca's key executives?

AstraZeneca's management team includes the folowing people:
  • Mr. Pascal Soriot, Exec. Director & CEO (Age 59)
  • Mr. Marc Dunoyer, Exec. Director & CFO (Age 66)
  • Ms. Pam P. Cheng, Exec. Vice-Pres of Operations & Information Technology (Age 47)
  • Mr. Jefrey Pott, Gen. Counsel
  • Ms. Katarina Ageborg, Exec. VP of Sustainability & Chief Compliance Officer

How do I buy shares of AstraZeneca?

Shares of AZN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is AstraZeneca's stock price today?

One share of AZN stock can currently be purchased for approximately GBX 5,591.

How big of a company is AstraZeneca?

AstraZeneca has a market capitalization of £61.66 billion.

What is AstraZeneca's official website?

The official website for AstraZeneca is http://www.astrazeneca.com/.

How can I contact AstraZeneca?

AstraZeneca's mailing address is 1 Francis Crick Avenue Cambridge Biomedical Campus, CAMBRIDGE, CB2 0AA, United Kingdom. The biopharmaceutical company can be reached via phone at +44-20-73045000.


MarketBeat Community Rating for AstraZeneca (LON AZN)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  1,287 (Vote Outperform)
Underperform Votes:  1,468 (Vote Underperform)
Total Votes:  2,755
MarketBeat's community ratings are surveys of what our community members think about AstraZeneca and other stocks. Vote "Outperform" if you believe AZN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AZN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/15/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel